Search - tctmd.com

Displaying 1 - 5 of 5

Sort: Relevancy | Date

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presentation AHA 2023

Effects of intensive blood pressure lowering treatment in reducing risk of cardiovascular events

Presenter: Jing Li

November 16, 2023

Magnitude of Antihypertensive Effect After Renal Denervation: Is It Sufficient for High-Risk as Well as Low-Risk Patients?

Presentation TCT 2019

Magnitude of Antihypertensive Effect After Renal Denervation: Is It Sufficient for High-Risk as Well as Low-Risk Patients?

Presenter: Justin Davies

September 28, 2019

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presentation EAS 2018

LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: a Mendelian randomization analysis

Presenter: Brian A. Ference

May 07, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.